BioSpace News Archive

The Swedish Companies Registration Office has approved and registered the company’s change of name from Pharmalink AB to Calliditas Therapeutics AB.

Brain Power’s campaign raised more money and a higher percentage of its goal in one day than any previous autism-related campaigns in their full 30 or 60 days on IndieGoGo, which is the second-largest crowdfunding platform in the world. The campaign also trended at #2 on the platform.

The NSS-2 Bridge device is a small electrical nerve stimulator placed behind the patient’s ear.

Revenue for the three months ended September 30, 2017 was $1,900,701 as compared to $1,411,263 for the same period in 2016, an overall increase of approximately 35%.

The company has obtained positive results opening the way for the ALK1 kinase inhibitor discovery program to move on to the lead optimization phase.

The time and location of the presentations will be announced in due time.

O’Brien joins Relay Therapeutics with significant strategic human resources experience in the life sciences industry.

The acquisition was funded through proceeds from Imagia’s Series A financing that was initiated in December 2016 led by BDC Healthcare Venture Fund and joined by Fidelity Investments Canada ULC.

[15-November-2017] MADRID, November 15, 2017 /PRNewswire/ -- PharmaMar (MCE:PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre(R) (PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without

The trial is now recruiting patients at 15 clinical sites in four European countries and should open soon in France.